The near-term timeline depends heavily on rentosertib, an Insilico Medicine drug targeting TNIK for idiopathic pulmonary fibrosis (IPF). Rentosertib is widely recognized as the principal advanced asset directed at a genuinely novel, AI-nominated target AI Drug Discovery FDA Approvals: The 2026 Reality Check https://intuitionlabs.ai/articles/ai-discovered-drugs-clinical-trials-2026. Its earlier Phase 2a trial does not qualify because its primary endpoint was safety, not efficacy, and the results predate the window TNIK A generative AI-discovered TNIK inhibitor for idiopathic .... Consequently, the immediate focus is the GENESIS-IPF-3 Phase 3 trial, which plans to enroll 320 patients and measure the annual decline in forced vital capacity over 52 weeks Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI ... https://www.prnewswire.com/news-releases/insilico-medicine-doses-first-patient-in-genesis-ipf-3-the-worlds-first-phase-iii-trial-of-a-generative-ai-driven-innovative-drug-302873749.html Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI ... Insilico Medicine Doses First Patient in GENESIS-IPF-3, .... With dosing initiated in September 2026 and an estimated primary completion date of October 30, 2029 https://clinicaltrials.gov/api/v2/studies/NCT07687459, a topline public report would typically arrive between late 2029 and early 2030.

Rentosertib’s success is far from guaranteed, and its eligibility under strict criteria carries some risk. IPF Phase 3 trials have a high failure rate, and the preceding Phase 2a signal was limited to small patient cohorts over just 12 weeks, making the probability of hitting the primary efficacy endpoint roughly 40–45%. There is also a notable adjudication risk: mebendazole, an approved drug, was identified in the literature as a TNIK inhibitor prior to Insilico’s AI nomination Insilico Medicine Launches Phase III Trial for AI-Developed ... and NCK-interacting kinase inhibitor Emergence of TNIK inhibitors in cancer therapeutics. Although the background context highlights rentosertib as the defining AI-nominated novel-target asset, a strict interpretation of the rule requiring that "no drug acting on the target had entered human trials" could theoretically disqualify TNIK.

If GENESIS-IPF-3 fails, is delayed, or is disqualified, the timeline shifts significantly into the 2030s. While there are over 100 AI-enabled clinical assets in development, most act on previously validated targets or do not meet the strict target-nomination criteria. For example, BenevolentAI's BEN-8744 acts on PDE10, a target previously hit by other drugs in human trials Artificial Intelligence–Designed Drugs in 2026: Clinical Pipeline .... However, AI capabilities in drug discovery are accelerating rapidly, as evidenced by agents running wet-lab experiments and drafting regulatory documents at unprecedented speeds. New, genuinely AI-nominated targets identified between 2026 and 2028 will require about 4 to 6 years to move from nomination through IND-enabling studies, Phase 1 safety testing, and a randomized Phase 2 efficacy trial with at least 50 patients. Considered alongside related estimates of clinical-trial volume, these timelines warrant substantial weight on delays: the broader AI-enabled pipeline does not necessarily provide enough qualifying trials to offset slippage in the leading asset.

The final date estimates reflect these two distinct phases of opportunity. The 10th percentile, June 1, 2029, accounts for the possibility of early trial completion or an undisclosed AI-nominated Phase 2 trial reading out. The 25th percentile, March 1, 2030, is driven by the expected GENESIS-IPF-3 readout, incorporating standard clinical trial slippage of 6 to 12 months and a combined probability of success and eligibility near 35–40%. The median, August 1, 2031, also reflects the high chance of delays and the limited number of qualifying opportunities suggested by related clinical-trial volume estimates, rather than assuming that the leading trial reports on schedule or that another asset promptly fills the gap. The 75th and 90th percentiles, March 1, 2034, and January 1, 2038, represent the fallback scenario where rentosertib fails or is disqualified, meaning the milestone must wait for the next generation of purely AI-nominated targets to progress through multi-year clinical pipelines.